Gerald Wiegand, PhD, MBA

Find him on :

Specialization

Gerald Wiegand is a senior biopharmaceutical executive with more than 25 years of experience in general management, commercial leadership, market access and organisational transformation across oncology, rare diseases, molecular diagnostics and vaccines. Based in Germany, he supports life sciences companies in building high-performing organisations, preparing launches and accelerating sustainable commercial growth.

His experience combines scientific depth with executive-level commercial leadership. Gerald has established and led local organisations from the ground up, shaped go-to-market models, negotiated access pathways and built cross-functional teams able to deliver in complex and highly regulated markets. At Vim Vitae, he brings particular value to assignments involving Germany, DACH market entry, launch preparation, market access and commercial scale-up.

Key expertise areas

Notable engagements

Moderna Germany & Austria: As General Manager, established Moderna’s presence across Germany and Austria, building the local organisation and leading the transition from pandemic vaccine delivery to sustainable commercial operations. He also supported launch and access preparation for mRNA programmes in rare diseases and oncology.
Takeda Germany: Led the Rare Metabolic Diseases business through major post-merger integration and transformation, maintaining a market-leading team while driving growth, key-account management and patient-centric initiatives.
Genomic Health Germany (acquired by Abbott) : Built the German affiliate from scratch for Oncotype DX, securing innovative access and reimbursement pathways, developing KOL education and guideline inclusion, and creating a lean cross-functional commercial organisation.
ALM e.V.: As founding Managing Director of Germany’s association of accredited medical laboratories and pathologies, developed the organisation’s governance, political strategy and institutional stakeholder engagement.

Market and academic background

Gerald began his career in biophysics and biotechnology, including work on novel proteomic assay technology in the United States. He holds a PhD in Physics / Biophysics from the Technical University of Munich and an MBA from INSEAD. His career spans scientific innovation, pharmaceutical commercial leadership, public affairs and healthcare-market transformation, providing him with a rare ability to connect technology, patient value and commercial execution.

Our team